Corcept Says EU Panel Backs Ovarian Cancer Drug Combination for Approval

08:36 AM EDT, 09/18/2026 (MT Newswires) -- Corcept Therapeutics (CORT) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use recommended that the European Commission approve relacorilant in combination with nab-paclitaxel to treat patients with platinum-resistant ovarian cancer. The recommendation was based on data from the Phase 2 and pivotal Phase 3 ROSELLA trials, in which the drug combination showed improved progression-free and overall survival versus nab-paclitaxel alone, the company said. The combination's safety profile was consistent with that of nab-paclitaxel monotherapy. The European Commission is expected to issue a final decision in Q4, Corcept Therapeutics said.